SOURCES SOUGHT
A -- ANTIVIRAL AGENTS DESIGNED FOR THE SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HIV
- Notice Date
- 6/16/2004
- Notice Type
- Sources Sought
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Energy, Idaho Nat'l Engineering and Environmental Laboratory (DOE Contractor), Idaho National Engineering & Environmental Laboratory, 2525 Fremont P.O. Box 1625, Idaho Falls, ID, 83415-3920
- ZIP Code
- 83415-3920
- Solicitation Number
- 04-13
- Response Due
- 7/15/2004
- Archive Date
- 7/30/2004
- Point of Contact
- Steve Paschke, Senior Business Specialist, Phone 208-526-1113, Fax 208-526-0876,
- E-Mail Address
-
sdp@inel.gov
- Description
- IDAHO NATIONAL ENGINEERING AND ENVIRONMENTAL LABORATORY SEEKS INDUSTRIAL PARTNERS CAPABLE OF COMMERCIALIZING ANTIVIRAL AGENTS DESIGNED FOR THE SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HIV. Announcement: Idaho National Engineering and Environmental Laboratory (INEEL), operated by Bechtel BWXT Idaho, LLC (BBWI) under contract with the Department of Energy (DOE) is soliciting a written indication of interest from industrial partners capable of developing, implementing, and commercializing BBWI proprietary antiviral agents designed for the selective destruction of cells infected with HIV, and who are interested in entering into a license agreement, research and development agreement, or both, for the purpose of developing and commercializing antiviral agents designed for the selective destruction of cells infected with HIV for human therapeutic applications. License terms would include an up-front licensing payment, minimum annual royalties and a running royalty based on a percentage of sales. A research and development agreement would be under a standard CRADA arrangement with an option for licensing subject inventions. Note: THIS IS NOT A COMMITMENT BY BBWI TO ENTER INTO EITHER A LICENSE AGREEMENT OR A COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR THESE TECHNOLOGIES WITH ANY COMPANY. A description of the technology follows: Antiviral agents have been designed for the selective killing of cells infected with the human immunodeficiency virus (HIV). The agent is described in US Patent No. 6,627,197. Briefly, the agents combine the lethal effect of the toxin ?ricin,? with cell targeting and HIV-specific enzymatic activities to achieve its selective destruction capability. Ricin is comprised of two polypeptide chains, A and B, linked together. The A chain is the toxin. The B chain facilitates cell binding and entry. Ricin is non-toxic until the link between the A and B chains is cleaved. After entering an infected cell the link is cleaved by an HIV-specific enzyme and the toxic A chain is released, killing the cell before it produces new viral particles. By design, cells without the HIV-specific enzyme are not harmed. This agent may enter both infected and uninfected cells. Its selectivity comes from the presence of an HIV-specific protease enzyme. If the enzyme is present, the cell is killed. Many different targeting compounds can be used in various permutations of this antiviral agent. More details will be available to qualified companies under a nondisclosure agreement. The successful company will be expected to: a) be capable of funding the development of the antiviral agents, b) have expertise in the development of antiviral agents involving toxins and, c) have the ability to commercialize the product of these developmental activities. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing BBWI's designs of antiviral agents for the selective destruction of cells infected with HIV should provide a written statement of interest, which includes the following: 1) company name and address; 2) the name, address, telephone number and e-mail address for a point of contact; 3) a brief description of corporate expertise and facilities relevant to commercializing this technology; and 4) a brief description of how the company might commercialize this technology. The statement of interest should be made by US mail or e-mail and should be received within 30 days of publication of this opportunity at the following address: John R. Snyder, Ph.D., Advisory Account Executive, Technology Outreach, BBWI, P.O. Box 1625, Idaho Falls, ID 83415-3805. E-mail is snydjr@inel.gov.
- Record
- SN00604341-W 20040618/040616211831 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |